An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease.
about
Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice.The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?[¹²⁵I]SD-7015 reveals fine modalities of CB₁ cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's diseaseEpigenetic regulation of fatty acid amide hydrolase in Alzheimer diseaseBlood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteinsThe influence of cannabinoids on generic traits of neurodegeneration.Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.The role of cannabinoids and leptin in neurological diseases.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.Indirubin-3'-monoxime suppresses amyloid-beta-induced apoptosis by inhibiting tau hyperphosphorylationThe effect of cadmium on Aβ levels in APP/PS1 transgenic mice.β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors.Antioxidant and Cholinesterase Inhibitory Activities of Ethyl Acetate Extract of Terminalia chebula: Cell-free In vitro and In silico Studies.A column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method to determine anandamide and 2-arachidonoylglycerol in plasma samples.Anandamide Effects in a Streptozotocin-Induced Alzheimer's Disease-Like Sporadic Dementia in Rats
P2860
Q30506148-E348223B-DEEC-40FD-B9F0-E35CF1E42F93Q33630562-A7E941CE-E00D-4043-8A85-34EA1950682DQ34269852-B974836D-A5B2-4A02-BD3A-616237B6B14AQ34312272-7F9DA4E4-4ADE-4F54-936A-B98925038BA7Q37347834-F32EEA73-5705-443F-B117-9973B0303709Q38156518-D2B7ED26-F8DB-488F-94F4-D049F0F4A180Q38196398-711A60CC-15C9-41F5-9A92-AAA1F02F63CDQ38395251-F6C892AC-DE78-4978-BCEA-F45DECDEE236Q38423817-99BDFEBE-E02C-4837-91B1-EEF661BF8182Q38563981-3E8E172A-7C46-493B-ACB9-98E219AD9713Q41943398-A6E62904-6CD5-4A59-B5EF-0BAE65BE7A18Q41977036-EC1CC3A3-3E3F-49AC-991C-A023BB74E245Q42272971-8EF255D6-948A-4202-8732-ACF60CB5EA00Q46260718-CE50A621-7479-41CF-9429-4D3522FABAC0Q50777459-39A08949-C84A-4F8A-B9B1-C32A7DBB9544Q58552816-F8EBB7BD-A7E4-49D3-8D3D-575DEA627B80
P2860
An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
An amyloid β42-dependent defic ...... nction in Alzheimer's disease.
@ast
An amyloid β42-dependent defic ...... nction in Alzheimer's disease.
@en
type
label
An amyloid β42-dependent defic ...... nction in Alzheimer's disease.
@ast
An amyloid β42-dependent defic ...... nction in Alzheimer's disease.
@en
prefLabel
An amyloid β42-dependent defic ...... nction in Alzheimer's disease.
@ast
An amyloid β42-dependent defic ...... nction in Alzheimer's disease.
@en
P2093
P2860
P921
P1476
An amyloid β42-dependent defic ...... unction in Alzheimer's disease
@en
P2093
Carl W Cotman
Daniele Piomelli
David H Cribbs
Elizabeth Head
Sevil Yasar
Vitaly Vasilevko
P2860
P304
P356
10.1016/J.NEUROBIOLAGING.2011.03.012
P577
2011-05-04T00:00:00Z